For 80% of colorectal cancers, Janus kinase (JAK) inhibitors may be effective
the ONA take:
According to a new study published in the journal Science Signaling, a team of researchers from around the world has demonstrated that more than 80% of colorectal cancers could be treated with Janus kinase (JAK) inhibitors. For the study, researchers tested JAK inhibitors in preclinical models of colorectal cancer and human colorectal cancer cells that have elevated levels of Wnt signaling.
A genetic mutation triggers increases levels Wnt pathway signaling, which in turn triggers more than 80% of colorectal cancers. According to the researchers, targeting the Wnt signaling pathway is difficult because normal cells in the intestine require low levels of Wnt signaling to maintain the healthiness of the gut.
The researchers sought to determine whether another signaling pathway, which involves JAK proteins, could be targeted to decrease tumor growth without harming the normal cells of the intestine. They found that inhibiting JAKs could halt cancer growth and no adverse effects were observed in the preclinical models; however, JAK inhibitors were only effective when the colorectal tumors were triggered by defective Wnt signaling, which is about 80-90% of colorectal cancers.
There are currently no JAK inhibitors approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer.
More than 80% of colorectal cancers could be treated with Janus kinase inhibitors
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|